Hepatitis E vaccine development: A 14-year odyssey

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 823-827

  Wu, Ting ^a   Li, Shao Wei ^a   Zhang, Jun ^a   Ng, Mun Hon ^a   Xia, Ning Shao ^a   Zhao, Qinjian ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Key words

Indexed keywords

ALANINE AMINOTRANSFERASE; HECOLIN; HEPATITIS ANTIBODY; HEPATITIS E VACCINE; HEV 239; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA; VIRUS VACCINE;

ANTIGEN BINDING; BINDING AFFINITY; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS E; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RISK; LIVER INJURY; NONHUMAN; NOTE; OPEN READING FRAME; PROCESS OPTIMIZATION; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 84863650285     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20042     Document Type: Note

References (16)

1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet 2012 DOI:10.1016/S0140-6736(11)61849-7
2. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008; 48:494-503; PMID:18192058; http://dx.doi.org/10.1016/j. jhep.2007.12.008.
3. Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int 2008; 28:1190-9; PMID:18662274; http://dx.doi.org/10.1111/j.1478-3231.2008.01840.x.
4. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369:1260; PMID:17434400; http:// dx.doi.org/10.1016/S0140-6736(07)60595-9.
5. Teshale EH, Howard CM, Grytdal SP, Handzel TR, Barry V, Kamili S, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis 2010; 16:126-9; PMID:20031058; http://dx.doi.org/10.3201/eid1601.090764.
6. Zhuang H, Cao XY, Liu CB, Wang GM. Epidemiology of hepatitis E in China. Gastroenterol Jpn 1991; 26(Suppl 3):135-8; PMID:1909252.
7. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebocontrolled, phase 3 trial. Lancet 2010; 376:895-902; PMID:20728932; http://dx.doi.org/10.1016/S0140-6736(10)61030-6.
8. Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; http://dx.doi.org/10.1016/j. vaccine.2004.11.064.
9. Zhang J, Gu Y, Ge SX, Li SW, He ZQ, Huang GY, et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005; 23:2881- 92; PMID:15780737; http://dx.doi.org/10.1016/j.vaccine.2004.11.065.
10. Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci U S A 2011; 108:10266-71; PMID:21642534; http:// dx.doi.org/10.1073/ pnas.1101309108.
11. Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 2009; 5:e1000537; PMID:19662165; http://dx.doi.org/10. 1371/journal.ppat.1000537.
12. Zhang JZ, Ng MH, Xia NS, Lau SH, Che XY, Chau TN, et al. Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein. J Med Virol 2001; 64:125-32; PMID:11360244; http://dx.doi.org/10.1002/jmv.1027.
13. Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27:1869-74; PMID:19168109; http://dx.doi.org/10.1016/j.vaccine.2008.12.061.
14. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, et al. Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis. Hepatology 2011; In press; PMID:22161542; http:// dx.doi.org/10.1002/hep.25522.
15. Sarin SK, Kumar M. A vaccine for hepatitis e: has it finally arrived? Gastroenterology 2011; 140:1349-52, discussion 1352-3; PMID:21354166; http://dx.doi. org/10.1053/j.gastro.2011.02.040.
16. Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr., Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903; PMID:17329696; http://dx.doi. org/10.1056/NEJMoa061847.